MedTrace Logo

A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer

NCT00436423 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2007-11-01

No results posted yet for this study

Summary

The primary objective of the study is to Evaluate the response rate of Gemcitabine with TS-1 in Korean patient with advanced but inoperable, metastatic or recurrent pancreatic cancer who is not receiving anti cancer therapy.

Conditions

  • Pancreatic Neoplasm
  • Neoplasm Metastasis

Interventions

DRUG

gemcitabine, TS-1

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Seoul Municipal Boramae Hospital

    collaborator UNKNOWN

  • Konkuk University Hospital

    collaborator OTHER

  • Korea University Ansan Hospital

    collaborator OTHER

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Korea University Guro Hospital

    collaborator OTHER

  • Korea University Anam Hospital

    lead OTHER

Principal Investigators

  • YeulHong Kim, professor · Korea University Anam Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436423 on ClinicalTrials.gov